Background: Polycystic ovary syndrome (PCOS) is a common endocrine–metabolic disorder linked to insulin resistance and hyperandrogenism. Gut microbiota–derived metabolites, including short-chain fatty acids (SCFAs), indoles, and bile acids, influence endocrine and metabolic pathways. Yet, no systematic review has specifically examined metabolite-targeted interventions in PCOS. Objective: To assess the effects of probiotic-derived metabolite interventions on hormonal and metabolic outcomes in women with PCOS. Methods: Following PRISMA 2020 and a PROSPERO-registered protocol (CRD42025543210), we searched MEDLINE, Embase, Web of Science, Scopus, Cochrane CENTRAL, and two Chinese databases to May 2025 without language restrictions. Eligible studies were randomized or quasi-randomized controlled trials ≥8 weeks. Two reviewers independently screened, extracted data, and assessed risk of bias (RoB 2). Pooled analyses used random-effects models, and evidence certainty was appraised with GRADE. Results: Seventeen trials (n = 1, 214 women) were included, testing synbiotics (6), probiotics (7), sodium butyrate (2), Akkermansia muciniphila (1), and an SCFA blend (1). Interventions significantly reduced total testosterone (MD −0.19 ng/mL, 95% CI −0.30 to −0.08), LH/FSH ratio (SMD −0.46; 95% CI −0.66 to −0.26), fasting insulin (MD −2.4 µIU/mL; 95% CI −3.9 to −0.9), and HOMA-IR (MD −0.49; 95% CI −0.78 to −0.19). HDL-C increased modestly (MD + 3.2 mg/dL; 95% CI + 0.7 to +5.6). Evidence certainty was moderate for insulin-related outcomes and low for sex-hormone outcomes. Conclusion: STargeting gut-derived metabolites, particularly with sodium butyrate and multi-strain synbiotics, improves hormonal and metabolic markers in PCOS. Larger multicenter RCTs with metabolomic confirmation are warranted to establish clinical translation. Systematic review registration: https://www.crd.york.ac.uk/prospero/ , identifier CRD42025543210.

Background: This 24-week randomized controlled trial aimed to evaluate the impact of multistrain probiotic supplementation on telomere length in patients with type 2 diabetes (T2DM). The study also assessed secondary outcomes including high-sensitivity C-reactive protein (hs-CRP) and glycated hemoglobin (HbA1c). Methods: A total of 124 participants with T2DM were randomly assigned to either a probiotic group (n = 62) or a placebo group (n = 62). Participants in the probiotic group consumed a supplement containing fourteen live microbial strains, including Lactobacillus plantarum, L. fermentum, L. acidophilus, L. casei, L. rhamnosus, L. reuteri, L. salivarius, L. paracasei, L. gasseri, Bifidobacterium bifidum, B. lactis, B. breve, Streptococcus thermophilus, and Saccharomyces boulardii, with each strain providing 2.148 billion CFUs per capsule, totaling 30 billion CFUs. The placebo group received vitamin B12 capsules without probiotics. The primary outcome was telomere length, and secondary outcomes included hs-CRP and HbA1c levels. Data were analyzed using intention-to-treat (ITT) and per-protocol (PP) methods. Results: The probiotic group exhibited a statistically significant decrease in telomere shortening compared to the placebo group (p < 0.001). The hs-CRP levels decreased more significantly in the probiotic group (p < 0.001), suggesting potential anti-inflammatory effects. The HbA1c levels improved in the probiotic group, with a reduction of 0.44% (p = 0.004). An age-stratified analysis revealed more substantial improvements in the 30–49 years cohort, which showed greater reductions in telomere shortening, inflammatory markers, and metabolic indicators compared to the 50–69 years group. Conclusions: Multistrain probiotic supplementation shows potential benefits in reducing telomere shortening and improving glycemic control. However, further long-term studies are needed to understand the underlying mechanisms and therapeutic implications of probiotics in T2DM. Trial registration: This trial was registered at the Clinical Trials Registry-India (CTRI/2023/07/055647).

Psoriasis, a chronic immune-mediated inflammatory skin disorder, presents complex pathogenetic mechanisms potentially influenced by viral infections. This comprehensive study explored the possible interplay of resistance and viral infections among psoriasis patients using serological screening techniques. The investigation involved 90 patients aged 23–45 years, systematically examining viral seropositivity for HSV (herpes simplex virus), HZ (herpes zoster), HBV (hepatitis B virus), HIV (human immunodeficiency virus), and HCV (hepatitis C virus) through ELISA testing. The findings revealed notable active or recent viral infection rates: 8.9% HSV positivity, 2.2% HZ antibody detection, 4.4% HCV positivity, and 4.4% HIV positivity. The research can contribute to current knowledge gaps, broaden the knowledge regarding the relationship between psoriasis and viral infection, and assess resistance, as it can mediate the interaction. The results can lead to improved diagnosis, treatment, and patient care options. This study emphasizes the importance of thorough viral testing for psoriasis patients, as well as focused therapeutic regimens that take into account viral co-infections. It elucidates the complex networks of biological relationships between immune factors, contributes information that is critical to our understanding of the multifactorial etiology of psoriasis, and concludes with a strong argument for investigating the mechanisms of viral involvement in this chronic-relapsing inflammatory disease.

Introduction: Probiotics, which are classified as helpful living microorganisms, have demonstrated the ability to improve salivary function, inhibit pathogens like Streptococcus mutans, and modify the oral and gut microbiota. The aims of this systematic review was to assess their effects on salivary function, oral microbiota, and gut health. Methods: Literature search was done in PubMed, Scopus, Web of Science, Science Direct and Cochrane were performed. Randomized controlled trials were included which involved human subjects receiving probiotic supplementation Outcomes assessed were salivary parameters (flow rate, buffering capacity, pH, biomarkers), oral microbiota changes, and gut health indicators. Study selection, data extraction, and risk of bias assessment (RoB 2.0) were performed independently by two reviewers. Due to heterogeneity, meta-analysis was not conducted. Results: A total of six systematic reviews were included in this review. Probiotic supplementation was associated with improvements in salivary parameters, including buffering capacity and plaque pH, and reductions in cariogenic bacteria such as Streptococcus mutans . Probiotics demonstrated beneficial effects on gut microbiota and gastrointestinal symptoms, supporting an oral–gut microbiota interaction. Risk of bias ranged from low to high across studies. Overall, evidence suggested beneficial effects, though heterogeneity and methodological limitations reduced certainty. Conclusions: Probiotics have been shown to provide modest, strain-specific benefits for modulating the oral microbiota and certain salivary parameters, with more precise molecular and clinical evidence for gut effects. Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD420251243347 , identifier CRD420251243347.